See every side of every news story
Get Started
SubscribeLogin
Israel-Hamas Conflict
Baseball
Natural Disasters
Social Media
Tariffs
Tennis
Soccer
Golf
Donald Trump
Floods
Boxing
Hockey
NBA
Published • loading... • Updated

Study confirms approved Ocrevus dose as optimal for relapsing MS

Summary by Multiple Sclerosis News Today
No added benefit was found in increasing the dose of Genentech’s Ocrevus (ocrelizumab) — to two to three times the currently approved 600 mg dose — in slowing disability progression in adults with relapsing multiple sclerosis (MS), according to new data from a Phase 3 clinical study. The study, called MUSETTE (NCT04544436), did not meet […] The post Study confirms approved Ocrevus dose as optimal for relapsing MS appeared first on Multiple Scler…
DisclaimerThis story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.

1 Articles

All
Left
Center
Right
Multiple Sclerosis News TodayMultiple Sclerosis News Today

Study confirms approved Ocrevus dose as optimal for relapsing MS

No added benefit was found in increasing the dose of Genentech’s Ocrevus (ocrelizumab) — to two to three times the currently approved 600 mg dose — in slowing disability progression in adults with relapsing multiple sclerosis (MS), according to new data from a Phase 3 clinical study. The study, called MUSETTE (NCT04544436), did not meet […] The post Study confirms approved Ocrevus dose as optimal for relapsing MS appeared first on Multiple Scler…

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • There is no tracked Bias information for the sources covering this story.
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

Multiple Sclerosis News Today broke the news in on Friday, April 4, 2025.
Sources are mostly out of (0)
Stories disproportionately reported by the Left or the Right

Similar News Topics

You have read out of your 5 free daily articles.

Join us as a member to unlock exclusive access to diverse content.

News
For You
SearchBlindspotLocal